To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Insulin; Insulin aspart
Indications Cardiovascular disorders; Diabetic angiopathies; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms NICE

11 Sep 2008 Primary endpoint composite cardiovasular events has been met. Results presented at EASD
14 Jan 2008 Biomarkers information updated
17 Dec 2007 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com